Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience:

Eufemia Stefania Lutrino,Laura Orlando,Antonio Febbraro,Mariangela Giampaglia,Claudio Zamagni,Paola Schiavone,Claudio Scavelli,Gianluca Dima,Palma Fedele,Guido Giordano,Domenico Bilancia,Anna Maria Quaranta,Daniela Rubino,Gianfranco Filippelli,Caterina Fontanella,Chiara Caliolo,A. Marino,Nicola Calvani,Pasqualinda Ferrara,Saverio Cinieri

Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience:

2019

Background:Chemotherapy plus targeted therapy is the established treatment for human epidermal growth factor receptor 2 (HER2)–overexpressing breast cancer (BC). Limited data regarding the safety a...

Keywords:

Pathology
Trastuzumab
Medicine
HER2 Positive Breast Cancer
Eribulin
Oncology
Internal medicine
Breast cancer
Chemotherapy
Targeted therapy
Human Epidermal Growth Factor Receptor 2
advanced breast
Cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations